Skip to main content

ClearPoint Neuro, Inc.

CLPT
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001285550

No open-market purchases or sales by ClearPoint Neuro, Inc. insiders were filed in the last 90 days; 129 institutions reported holding it in 13F filings for Q2 2026, worth $247.9M in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 29, 2026, 1:13 AM ET

Revenue flow, FY2025

Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2025: $25.5M (69.1% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of ClearPoint Neuro, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedJan 12, 2026Feb 26, 2025Jan 8, 2024Jan 11, 2023Feb 14, 2022
Revenue$37.0M$31.4M$24.0M$20.6M$16.3M
Cost of revenue$14.3M$12.3M$10.3M$7.02M$5.01M
Gross profit$22.7M$19.1M$13.6M$13.5M$11.3M
Research and development$13.9M$12.4M$11.7M$10.9M$8.98M
Selling, general and administrative$16.5M$12.0M$11.8M$9.61M$8.76M
Operating income-$24.2M-$19.7M-$22.4M-$16.3M-$13.4M
Interest expense–––$81.0K$973.0K
Income tax$55.0K$12.0K$8.00K$0$0
Net income-$25.5M-$18.9M-$22.1M-$16.4M-$14.4M
EPS, basic$-0.90$-0.70$-0.90$-0.68–
EPS, diluted$-0.90$-0.70$-0.90$-0.68–
Weighted shares, basic28.3M27.0M24.6M24.2M–
Weighted shares, diluted28.3M27.0M24.6M24.2M–
Margins and growth
Gross margin61.4%60.9%56.8%65.8%69.3%
Operating margin-65.4%-62.9%-93.7%-79.5%-82.1%
Net margin-69.1%-60.3%-92.2%-80.0%-88.4%
Revenue growth, year over year+17.8%+31.0%+16.6%+26.1%+27.0%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of ClearPoint Neuro, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedJan 12, 2026Feb 26, 2025Jan 8, 2024Jan 11, 2023Feb 14, 2022
Cash and equivalents$45.9M$20.1M$23.1M$27.6M$54.1M
Short-term investments––$0$9.87M–
Accounts receivable$6.55M$4.71M$3.21M$2.67M$2.34M
Inventory$8.36M$6.86M$7.91M$9.30M$4.94M
Total current assets$63.6M$33.4M$36.2M$51.2M$61.9M
Property, plant and equipment$2.62M$2.00M$1.39M$806.0K$539.0K
Goodwill$7.47M––––
Intangible assets$13.9M––––
Total assets$97.7M$39.2M$42.7M$55.5M$65.6M
Accounts payable$1.26M$1.34M$393.0K$272.0K$427.0K
Total current liabilities$10.8M$10.4M$7.43M$6.79M$4.75M
Long-term debt$49.1M–$9.95M$9.89M$9.84M
Total liabilities$69.7M$13.8M$21.5M$18.6M$16.8M
Shareholders' equity$28.0M$25.4M$21.2M$36.9M$48.8M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of ClearPoint Neuro, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedJan 12, 2026Feb 26, 2025Jan 8, 2024Jan 11, 2023Feb 14, 2022
Operating cash flow-$23.9M-$8.95M-$13.7M-$16.2M-$12.7M
Capital expenditures$522.0K$275.0K$717.0K$253.0K$168.0K
Free cash flow-$24.4M-$9.22M-$14.4M-$16.4M-$12.9M
Depreciation and amortization$814.0K$980.0K$626.0K$244.0K$159.0K
Stock-based compensation$8.18M$6.91M$6.08M$4.13M$2.08M
Investing cash flow$615.0K-$275.0K$8.95M-$10.7M-$168.0K
Financing cash flow$50.2M$6.19M$296.0K$409.0K$46.9M
Net change in cash$26.9M-$3.04M-$4.47M-$26.5M$34.0M
Ratio
Stock-based compensation, % of revenue22.1%22.0%25.4%20.1%12.7%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for ClearPoint Neuro, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Oct 21, 202632.1M+12.8%SEC
Jul 27, 202630.5M+7.3%SEC
May 7, 202630.0M+7.1%SEC
Mar 6, 202629.7M+7.4%SEC
Oct 27, 202528.4M+3.0%SEC
Aug 6, 202528.4M+3.0%SEC
May 7, 202528.0M+2.1%SEC
Feb 18, 202527.6M+2.4%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.